COVID-19 vaccine verdicts loom as next big market risk

  • 📰 Reuters
  • ⏱ Reading Time:
  • 14 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Optimism that vaccines are on the way to end the coronavirus pandemic has been a major factor in this year’s U.S. stock resurgence. That will face a critical test in coming weeks, as investors await clinical data on whether they actually work.

possible as soon as October or November. Disappointing results could further shake markets that have recently grown turbulent on worries over fiscal stimulus delays and uncertainty around the Nov. 3 U.S. presidential election.

The number of vaccines in development could blunt the negative market impact of any single setback. More than a half-dozen vaccines globally are in late-stage trials out of over 30 currently being tested in humans, according to the World Health Organization.

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

Why still use archaic buildings with screens everywhere? Why not use the internet?

All the data about vaccine timelines, about vaccine Innovation. In one handy White House report. Mitigating the impact of pandemic influenza through vaccine Innovation. From Sept 15th 2019.

Why is the entire English speaking media peddling a vax we will never have or need.

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 2. in RU

Россия Последние новости, Россия Последние новости